Influenza A virus H5N1 vaccine - SolvayAlternative Names: Pandemic H5N1 egg-based vaccine - Solvay
Latest Information Update: 03 Jun 2009
At a glance
- Originator Solvay Pharmaceuticals
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Influenza A virus H5N1 subtype